beraprost

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	19 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.671		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	4.688		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	47.534	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	5.129	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	10.490	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	14.980	%	High	1
herg	hERG pIC50	4.403	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	3.273	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.221	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	6.730	%	High	1
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1	23
kinase-selectivity-class	GRK2,MAP2K6	2
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	7.980		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	26.242		High	1
mppb	Mouse plasma protein binding (% unbound)	13.170		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	13.062		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	13.980	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	19.679	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	82.120	%	High	1
rppb	Rat plasma protein binding (% unbound)	6.830	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	859.014	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary hypertension	136.63	31.83	53	3220	42470	90582704
Cardiac failure	132.90	31.83	69	3204	109427	90515747
Right ventricular failure	131.31	31.83	42	3231	19163	90606011
Concomitant disease aggravated	107.54	31.83	32	3241	11486	90613688
Hepatic function abnormal	85.73	31.83	39	3234	46249	90578925
Brain natriuretic peptide increased	84.57	31.83	23	3250	5982	90619192
Transfusion	82.73	31.83	29	3244	17459	90607715
Anaemia	78.56	31.83	79	3194	352723	90272451
Upper respiratory tract inflammation	71.06	31.83	17	3256	2655	90622519
Platelet count decreased	68.61	31.83	49	3224	136920	90488254
Gamma-glutamyltransferase increased	57.95	31.83	28	3245	37924	90587250
Blood pressure decreased	57.48	31.83	35	3238	74860	90550314
Iron deficiency anaemia	56.98	31.83	24	3249	23638	90601536
Pulmonary arterial hypertension	54.64	31.83	24	3249	26163	90599011
Interstitial lung disease	54.30	31.83	34	3239	76371	90548803
Aspartate aminotransferase increased	40.73	31.83	32	3241	102905	90522269
Haematocrit decreased	38.50	31.83	22	3251	41810	90583364
Renal impairment	37.93	31.83	31	3242	105390	90519784
Haemoglobin decreased	37.25	31.83	37	3236	161919	90463255
Pulmonary arterial pressure increased	37.05	31.83	11	3262	3905	90621269
Red blood cell count decreased	36.41	31.83	22	3251	46329	90578845
Alanine aminotransferase increased	32.84	31.83	30	3243	118308	90506866

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Right ventricular failure	99.15	31.77	28	1332	9527	42610448
Concomitant disease aggravated	76.06	31.77	21	1339	6565	42613410
Brain natriuretic peptide increased	61.94	31.77	18	1342	6752	42613223
Cardiac failure	59.92	31.77	39	1321	106817	42513158
Pulmonary hypertension	56.61	31.77	23	1337	23546	42596429
Pulmonary arterial hypertension	35.34	31.77	13	1347	10174	42609801

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Right ventricular failure	219.19	27.75	70	4834	25884	110558511
Pulmonary hypertension	181.20	27.75	74	4830	55146	110529249
Concomitant disease aggravated	175.43	27.75	53	4851	16311	110568084
Cardiac failure	167.94	27.75	104	4800	187522	110396873
Brain natriuretic peptide increased	140.58	27.75	41	4863	11168	110573227
Hepatic function abnormal	96.59	27.75	56	4848	89239	110495156
Anaemia	84.38	27.75	112	4792	546974	110037421
Transfusion	83.00	27.75	34	4870	25438	110558957
Upper respiratory tract inflammation	82.34	27.75	22	4882	4349	110580046
Pulmonary arterial hypertension	81.34	27.75	36	4868	32532	110551863
Platelet count decreased	79.19	27.75	72	4832	230371	110354024
Iron deficiency anaemia	63.44	27.75	30	4874	31529	110552866
Interstitial lung disease	58.83	27.75	49	4855	139285	110445110
Gamma-glutamyltransferase increased	52.19	27.75	33	4871	61276	110523119
Blood pressure decreased	51.77	27.75	42	4862	115049	110469346
Aspartate aminotransferase increased	47.25	27.75	46	4858	159890	110424505
Alanine aminotransferase increased	40.18	27.75	45	4859	183728	110400667
Haemoglobin decreased	38.29	27.75	51	4853	248676	110335719
Red blood cell count decreased	36.01	27.75	27	4877	65896	110518499
Pulmonary arterial pressure increased	35.84	27.75	12	4892	5115	110579280
Haematocrit decreased	33.73	27.75	26	4878	66091	110518304
Blood urea increased	33.38	27.75	24	4880	54933	110529462
Fatigue	32.86	27.75	7	4897	1215951	109368444
Renal impairment	31.09	27.75	40	4864	188405	110395990
Pleural effusion	29.76	27.75	38	4866	177671	110406724
Pulmonary congestion	29.72	27.75	18	4886	30948	110553447
Ascites	27.96	27.75	27	4877	92781	110491614

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

beraprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	B01AC19	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D006401	Hematologic Agents
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:50427	platelet aggregation inhibitor
CHEBI has role	CHEBI:66900	prostaglandin receptor agonist
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:231911	renoprotective agent
CHEBI has role	CHEBI:50249	anticoagulant

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostacyclin receptor	GPCR	P43119	PI2R_HUMAN	AGONIST	IC50	8.37	WOMBAT-PK	DRUG LABEL
Prostaglandin E2 receptor EP3 subtype	GPCR	P43115	PE2R3_HUMAN	AGONIST	Ki	6.17	IUPHAR
Prostaglandin E2 receptor EP4 subtype	GPCR	P35408	PE2R4_HUMAN	AGONIST	Ki	5.14	IUPHAR
Prostacyclin receptor	GPCR		PI2R_MOUSE	AGONIST	Ki	7.80	IUPHAR
Prostacyclin receptor	GPCR		PI2R_RAT	AGONIST	Ki	7.72	IUPHAR

ID	Source
D01551	KEGG_DRUG
88475-69-8	SECONDARY_CAS_RN
C0053336	UMLSCUI
CHEBI:135633	CHEBI
CHEMBL1207745	ChEMBL_ID
CHEMBL435883	ChEMBL_ID
DB05229	DRUGBANK_ID
C048081	MESH_SUPPLEMENTAL_RECORD_UI
6917951	PUBCHEM_CID
1967	IUPHAR_LIGAND_ID
6261	INN_ID
35E3NJJ4O6	UNII
010867	NDDF
010868	NDDF
35E3NJJ4O6	INXIGHT DRUGS